4D Molecular Therapeutics (4DMT) has initiated its Phase 3 clinical trial, 4FRONT-1, for 4D-150, a potential treatment for wet age-related macular degeneration (wet AMD). The trial aims to evaluate the efficacy and safety of 4D-150 compared to the current standard treatment, aflibercept. The company expects to release topline data from this trial and a second Phase 3 trial, 4FRONT-2, in the latter half of 2027.
This advancement is potentially transformative for wet AMD treatment. Current treatments require frequent intravitreal injections, impacting patient quality of life and creating a significant burden on healthcare systems. 4D-150 is designed for sustained delivery of anti-VEGF therapy with a single injection, potentially reducing the frequency of injections and improving the patient experience. This could lead to better patient compliance and potentially improved visual outcomes, while also freeing up physician and healthcare resources.
The 4FRONT-1 trial is a randomized, double-masked study comparing 4D-150 to aflibercept 2 mg administered every eight weeks. The primary endpoint is non-inferiority in best corrected visual acuity at 52 weeks. A key secondary endpoint focuses on the reduction in the number of injections needed over the 52-week period. The 4FRONT-2 trial, slated to begin in Q3 2025, will have a similar design but will include both treatment-naïve and previously treated patients globally.
The progression of 4D-150 into Phase 3 represents a significant milestone for 4DMT. Positive results from these trials could lead to regulatory approval and establish 4D-150 as a leading therapy for wet AMD. This would not only offer a more convenient and potentially more effective treatment option for patients but also position 4DMT for substantial growth in a large and growing market. The potential for a durable, single-injection treatment could reshape the wet AMD treatment landscape and significantly impact the lives of millions affected by this debilitating disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
